Alembic Pharmaceuticals Limited

rs,

Date: 5th May, 2023 To, The Manager, Department of Corporate Services, BSE Limited P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 Scrip Code:533573 To, The Manager, Listing Department, N

Rs. 250

nd: transition to direct marketing Formed a JV, Aleor, for dermatology portfolio Azithral crossed Rs. 250 Cr sales Mark as per ORG IMS, MAT December 2019 Azithral Ranked 16th Highest selling brand in IPM w

RS. 447

MAT December 2019 Azithral Ranked 16th Highest selling brand in IPM with sales reflection of over RS. 447 Cr. as per ORG IMS, MAT December 2022 (Source – IQVIA) Aleor Dermacuticals Ltd. has merged with Alem

22%

R&D R&D % EBIDTA Post R&D Margin % Net Profit* Capex Debt-Equity (Net) 14.06 14.16 3.16 22% 1.36 10% 2.05 15% 1.53 0.67 4.92 35% 3.50 25% 1.58 11% 0.22 1.06 -1% -36% -

10%

EBIDTA Post R&D Margin % Net Profit* Capex Debt-Equity (Net) 14.06 14.16 3.16 22% 1.36 10% 2.05 15% 1.53 0.67 4.92 35% 3.50 25% 1.58 11% 0.22 1.06 -1% -36% -61% 30% 59

15%

R&D Margin % Net Profit* Capex Debt-Equity (Net) 14.06 14.16 3.16 22% 1.36 10% 2.05 15% 1.53 0.67 4.92 35% 3.50 25% 1.58 11% 0.22 1.06 -1% -36% -61% 30% 598% 7% -21%

35%

t* Capex Debt-Equity (Net) 14.06 14.16 3.16 22% 1.36 10% 2.05 15% 1.53 0.67 4.92 35% 3.50 25% 1.58 11% 0.22 1.06 -1% -36% -61% 30% 598% 7% -21% -14% -27% -34% 56.53

25%

ebt-Equity (Net) 14.06 14.16 3.16 22% 1.36 10% 2.05 15% 1.53 0.67 4.92 35% 3.50 25% 1.58 11% 0.22 1.06 -1% -36% -61% 30% 598% 7% -21% -14% -27% -34% 56.53 13.01 53

11%

Net) 14.06 14.16 3.16 22% 1.36 10% 2.05 15% 1.53 0.67 4.92 35% 3.50 25% 1.58 11% 0.22 1.06 -1% -36% -61% 30% 598% 7% -21% -14% -27% -34% 56.53 13.01 53.06 16.40

1%

3.16 22% 1.36 10% 2.05 15% 1.53 0.67 4.92 35% 3.50 25% 1.58 11% 0.22 1.06 -1% -36% -61% 30% 598% 7% -21% -14% -27% -34% 56.53 13.01 53.06 16.40 23% 7.22 13%

36%

22% 1.36 10% 2.05 15% 1.53 0.67 4.92 35% 3.50 25% 1.58 11% 0.22 1.06 -1% -36% -61% 30% 598% 7% -21% -14% -27% -34% 56.53 13.01 53.06 16.40 23% 7.22 13% 6.80

61%

1.36 10% 2.05 15% 1.53 0.67 4.92 35% 3.50 25% 1.58 11% 0.22 1.06 -1% -36% -61% 30% 598% 7% -21% -14% -27% -34% 56.53 13.01 53.06 16.40 23% 7.22 13% 6.80 12%

“Product registrations as well as dossier extensions to new markets are on track to accelerate growth.”

“Anticipate good growth in API business for FY24 backed by strong orderbook.”

“4 Branded Business Revenue – Q4 FY23 INR Bn Revenue – Last 5 Years Vet Acute Speciality 4.49 0.53 1.49 2.46 4.90 0.61 1.70 2.58 13.8 14.3 15.0 CAGR - 11% 19.3 INR Bn 20.6 Q4FY22 Q4FY23 FY19 FY20 FY21 FY22 FY23 Marketing organization ➢ 5000+ MRs ➢ 18 Marketing divisions ➢ 15.8% Product portfolio in NLEM ➢ Prescribers around 2,30,000 Manufacturing facility ➢Sikkim Key achievements ➢ India Branded Business recorded 9% growth with topline of Rs 490 crores for Q4 FY 23.”

“10 Ex-US Generics Revenue : Q4 FY23 1.88 INR Bn Revenue – Last 5 Years 2.49 CAGR - 15% INR Bn 8.52 Q4FY22 Q4FY23 ➢ Ex-US driven by partnership.”

“➢ Presence in following key markets - Europe, Canada, Australia, Brazil and South Africa ➢ Future growth to be driven by New launches and territory expansions 7.79 7.75 4.94 4.97 FY19 FY20 FY21 FY22 FY23 11 API Revenue : Q4 FY23 2.22 INR Bn Revenue – Last 5 Years CAGR - 11% 3.13 INR Bn 11.66 9.55 9.39 Q4FY22 Q4FY23 7.71 7.08 ➢ Growth of 41% on QoQ basis is led by high off-take and better product mix in Q4.”

“➢ Expect steady growth for this business.”

Key Highlights

1

Safe Harbour Agreement

1

Key Highlights

Business Formulations India US Ex-US API Total Revenue 5.45 4.32 2.06 3.26 15.09 4.90 3.54 2.49 3.13 14.06 4.49 5.57 1.88 2.22 14.16 9% -36% 32% 41% -1% -10% -18% 21% -4% -7% 20.63 15.72 8.52 11.66 56.53 19.26 16.66 7.75 9.39 53.06 7% -6% 10% 24% 7% Business Breakup – YTD Mar’23 Ex-US 15% API 21% US 28% India 36% Speciality 19% Acute 12% Vet 5% India Branded Business : India Branded Business recorded 9% growth with topline of Rs 490 crores for Q4 FY23. Ex of Azithral, growth of India Branded Business is 12%. US Generics : The US business continues to remain challenging on account of competitive intensity. Volume grew by 18% due to the new launches and market share expansion Ex-US Generics : Sustainable business with growth of 10% on annualized basis. Demand outlook remains strong. Product registrations as well as dossier extensions to new markets are on track to accelerate growth. API : Strong momentum delivering growth of 24% on annualized basis, largely led by high off-take and bette

Safe Harbour Agreement

Materials and information provided during this presentation may contain ‘forward-looking statements’. These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Risks and uncertainties include general industry and market conditions and general domestic and international economic conditions such as interest rate and currency exchange fluctuations. Risks and uncertainties particularly apply with respect to product- related forward-looking statements. Product risks and uncertainties include, but are not limited, to technological advances and patents attained by competitors, challenges inherent in new product development including completion of clinical trials; claims and concerns about product safety and efficacy; obtaining regulatory approvals; domestic and foreign healthcare reforms; trend towards managed care and healthcare cost contai